Oramed Pharmaceuticals

Pharmaceutical company based in Israel

ORMP Tel Aviv Stock Exchange · home listing Tel Aviv Stock Exchange Nasdaq ORMP Nasdaq ISIN US68403P2039 SEC CIK 1176309 LEI 5299006K52ZIIGQJ6R84
Follow Oramed Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income $18.4M −62% vs same quarter last year
EPS, diluted $0.43 −61.9% vs same quarter last year
Operating cash flow $426K +126.2% vs same quarter last year
Operating income −$4.1M −69.1% vs same quarter last year
Revenue by quarter
$2M
$0
$0
$0
Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$2M$75.3K
FY24-−$15.9K
FY23$1.3M$5.1K
FY22$2.7M−$36.6M
FY21$2.7M-
FY20$2.7M-
FY19$2.7M-
FY18$2.4M-
FY17$2.5M-
FY16$641K-
FY15--
FY14--
FY13-$4.2M
FY12--
FY11-−$1.6M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY250.6%−754.4%3.8%
FY24---
FY23-−1176.8%0.4%
FY22-−1502%−1352.6%
FY21-−896.2%-
FY20-−433.8%-
FY1996.7%−541.3%-
FY18-−552.3%-
FY1792.4%−438.6%-
FY1623.6%−1561.6%-
FY15---
FY14---
FY13---
FY12---
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0$10MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$9.2M
FY24−$8.4M
FY23−$10.5M
FY22−$28.4M
FY21−$21.6M
FY20−$12.5M
FY19−$13M
FY18−$14.7M
FY17−$5.8M
FY16$4.6M
FY15−$4.9M
FY14−$4.1M
FY13−$3.4M
FY12−$2.3M
FY11−$1.7M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Oramed Pharmaceuticals
  • Healthcare median
−1500%−1000%−500%0%500%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOramed PharmaceuticalsHealthcare median
FY253.8%−30.6%
FY24-−47%
FY230.4%−58%
FY22−1352.6%−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%